Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
bioAffinity Technologies, Inc. is a biotechnology and diagnostics company focused on the development, commercialization, and clinical advancement of noninvasive cancer diagnostic tests, with an initial emphasis on lung cancer. The company operates primarily in the molecular diagnostics and oncology diagnostics industries, targeting earlier detection of cancer to improve patient outcomes and reduce healthcare costs.
The company’s primary product and revenue driver is CyPath® Lung, a laboratory-developed test designed to detect early-stage lung cancer from sputum samples in high-risk populations. bioAffinity Technologies positions itself through a noninvasive, cost-effective, and clinically differentiated diagnostic approach that complements existing imaging-based screening methods. The company was incorporated in 2014 and transitioned to a public company in 2022 following a merger with a special purpose acquisition company, marking its evolution from early-stage research to commercial diagnostics.
Business Operations
bioAffinity Technologies conducts its operations through its wholly owned commercial subsidiary, bioAffinity Diagnostics, LLC, which manages laboratory operations, clinical testing, and commercialization activities. The company generates revenue primarily from diagnostic testing services and related clinical laboratory activities, with a focus on physician-ordered tests for patients at elevated risk of lung cancer.
Operations are concentrated in the United States, where the company maintains its laboratory infrastructure, regulatory compliance under CLIA and CAP standards, and sales and marketing efforts. The company controls proprietary diagnostic technology based on flow cytometry and cell biomarker analysis. As of publicly available disclosures, bioAffinity Technologies does not report material joint ventures, and its business model is centered on internal development and commercialization rather than broad licensing partnerships.
Strategic Position & Investments
The company’s strategic direction emphasizes expanding adoption of CyPath® Lung, pursuing reimbursement coverage, and advancing additional cancer diagnostic applications using its underlying technology platform. Growth initiatives include clinical validation studies, physician outreach, and engagement with payers to support broader utilization in lung cancer screening protocols.
bioAffinity Technologies has invested primarily in internal research and development rather than large-scale acquisitions. Its strategic assets include intellectual property related to cancer biomarker detection and diagnostic workflows. Beyond lung cancer, the company has disclosed interest in applying its technology to other cancer indications; however, commercialization timelines and scope outside lung cancer remain data inconclusive based on available public sources.
Geographic Footprint
The company is headquartered in San Antonio, Texas, and its operational footprint is primarily within the United States. Laboratory services, clinical operations, and corporate management are U.S.-based, reflecting the company’s focus on the domestic diagnostics market and U.S. regulatory pathways.
While bioAffinity Technologies is publicly traded and accessible to international investors, it does not report significant international operations or material revenue from outside North America. Any future international expansion remains dependent on regulatory approvals and strategic partnerships, which have not been conclusively detailed in public filings.
Leadership & Governance
bioAffinity Technologies is led by an executive team with experience in diagnostics commercialization, healthcare operations, and life sciences management. The leadership emphasizes a strategy centered on early cancer detection, clinical validation, and disciplined commercialization.
Key executives include:
- Maria Zannes – President & Chief Executive Officer
- Charles J. Caracciolo – Chief Financial Officer
- Michael S. Watts – Chief Operating Officer
- Steven A. Anderson – Chief Commercial Officer
Public disclosures identify scientific founders and early contributors to the company’s diagnostic technology; however, specific attribution of a single founder role is data inconclusive based on available public sources. The company is governed by a board of directors consistent with U.S. public company standards, with oversight of strategy, risk, and regulatory compliance.